Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector (Aim 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02461628
Recruitment Status : Completed
First Posted : June 3, 2015
Results First Posted : October 29, 2019
Last Update Posted : October 29, 2019
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
Moi University
Information provided by (Responsible Party):
Duke University

Brief Summary:
The overall objective of this study is to evaluate the public health impact of targeted antimalarials subsidies through scale-up by determining the community-wide effects of targeting an antimalarial subsidy through a partnership between Community Health Volunteers (CHVs) and the private retail sector. The primary hypothesis to be tested is that offering a fixed-price voucher that reduces the cost for artemisinin combination therapy (ACT) purchase in the retail sector conditional on a positive malaria test (targeted subsidy) can improve uptake of testing for malaria and will increase the proportion of fevers tested for malaria before treatment. The study will be carried out in two sub-counties in Kenya with similar malaria burden but different access to health services; the investigators will use a cluster-randomized design to assign community units (CUs) in each sub-county to either an intervention or control arm. CHVs will be trained to use malaria rapid diagnostic tests (RDTs) to diagnose malaria in household members with documented or reported fever; households in intervention CUs will be informed of the intervention and encouraged to contact the CHV for any febrile illness in the home. There are minimal risks associated with receiving an RDT. Households with a positive RDT will be given a serialized voucher that will entitle the holder to purchase a quality assured ACT in the retail sector at a reduced, fixed price. The primary and secondary outcome measures will be compared at baseline and 12 months post-baseline through population-based surveying. The primary aim is to determine whether there is significant difference between the 2 study arms in the proportion of clients with fever who are tested prior to any treatment after adjusting for relevant covariates.

Condition or disease Intervention/treatment Phase
Fever Malaria Behavioral: Malaria RDT & conditional voucher for ACT from retail sector Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40340 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Innovative Partnership to Target Antimalarial Subsidies in the Retail Sector
Study Start Date : July 2015
Actual Primary Completion Date : May 26, 2017
Actual Study Completion Date : July 12, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever Malaria

Arm Intervention/treatment
Experimental: Malaria RDT & conditional voucher
In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified artemisinin combination therapy (ACT) at a reduced fixed price in the retail sector conditional on a positive test.
Behavioral: Malaria RDT & conditional voucher for ACT from retail sector
Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test

No Intervention: Comparison Arm
Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.



Primary Outcome Measures :
  1. Number of Subjects With a Fever Who Receive a Malaria Test From Any Source [ Time Frame: 6 months, 12 months, 18 months ]

Secondary Outcome Measures :
  1. Number of Participants Using ACT Who Had a Positive Test [ Time Frame: 6 months, 12 months, 18 months ]
  2. Number of Participants Using an ACT Who Did Not Have a Test [ Time Frame: 6 months, 12 months, 18 months ]
  3. Number of Subjects Who Received a Correct Dose of AL (Artemether Lumefantrine) [ Time Frame: 6 months, 12 months, 18 months ]
    Denominator is all those who took AL. Artemether lumefantrine is one type of ACT.

  4. Number of Subjects With Fever That Received Correct Treatment [ Time Frame: 6 months, 12 months, 18 months ]
    The number of people with fever that report receiving correct treatment with regards to malaria (i.e., received an RDT test and took ACTs if the result was positive, or did not take ACTs if the test result was negative).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA

Intervention participation criteria:

  • Client is older than 1 year
  • Client has fever or history of fever or feeling unwell with a malaria-like illness within the last 2 days
  • Client or their parent/legal guardian (if under 18) consents to participate

Cross sectional survey participation criteria:

  • Household representative in the intervention or control arm
  • At least one member in the respondent's household with a history of fever or feeling unwell with a malaria like illness within the last four weeks
  • Respondent is older than 18 years

EXCLUSION CRITERIA

Intervention exclusion criteria:

  • Client has signs of severe disease or other problem requiring immediate referral to a health facility
  • Client has already visited a health facility, taken or purchased antimalarials for the current illness.

Cross sectional survey exclusion criteria:

• Households not in the intervention or control arms


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02461628


Locations
Layout table for location information
Kenya
Moi University
Eldoret, Kenya
Sponsors and Collaborators
Duke University
National Institute of Allergy and Infectious Diseases (NIAID)
Moi University
Investigators
Layout table for investigator information
Principal Investigator: Wendy O'Meara, PhD Duke University
  Study Documents (Full-Text)

Documents provided by Duke University:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT02461628     History of Changes
Other Study ID Numbers: Pro00063384
5R01AI110478 ( U.S. NIH Grant/Contract )
First Posted: June 3, 2015    Key Record Dates
Results First Posted: October 29, 2019
Last Update Posted: October 29, 2019
Last Verified: October 2019
Keywords provided by Duke University:
Malaria
Antimalarial subsidy
Malaria rapid diagnostic test (RDT)
Public-private partnership
Community health workers
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Protozoan Infections
Parasitic Diseases
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents